<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_SDU-Denmark_Tour33 skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:SDU-Denmark/Tour33</SPAN></H1><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><DIV class="BackgroundLayout"><DIV class="top bannerShadow"><DIV class="NavbarContainer"><DIV class="NavbarContainerInner"><DIV class="MenuButton" id="btnWelcome"><A class="MenuButtonLink" href="https://2015.igem.org/Team:SDU-Denmark">Welcome</A></DIV><DIV class="MenuButton" id="btnTour"><A class="MenuButtonLink" href="https://2015.igem.org/Team:SDU-Denmark/Tour10">Interactive wiki-tour</A></DIV><DIV class="MenuButton" id="btnMenu"><A class="MenuButtonLink" href="#" id="btnMenu2">Menu</A><DIV class="menuPopup"><DIV class="menuPopupContent"><DIV class="menuPopupContentInner bannerShadow"><DIV class="menuIntro"><DIV class="warningBox"><P class="menuIntro">
You really should try our <A href="https://2015.igem.org/Team:SDU-Denmark/Tour10">interactive wiki tour</A> instead! 

</P></DIV><P class="menuIntro">
But if you are looking for a specific page - you are in the right place. 
</P><DIV class="menuItems"><UL><LI class="header"><A href="https://2015.igem.org/Team:SDU-Denmark/Tour10">Introduction</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour11">The Team</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour12">Attributions</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour13">Gallery</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour14">Medal Requirements</A></LI></UL><UL><LI class="header"><A href="https://2015.igem.org/Team:SDU-Denmark/Tour20"> Antibody Issue</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour21">Antibody Production</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour22">Animal Ethics</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour23">The Alternative</A></LI></UL><UL><LI class="header"><A href="https://2015.igem.org/Team:SDU-Denmark/Tour30">PAST</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour31">Two-Hybrid Screening</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour32">System Design</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour33">Business</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour34">Entrepreneurship</A></LI></UL><UL><LI class="header"><A href="https://2015.igem.org/Team:SDU-Denmark/Tour40">Process</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour41">Complete Journal</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour42">Collaborations</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour43">SOPs</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour44">Safety</A></LI></UL><UL><LI class="header"><A href="https://2015.igem.org/Team:SDU-Denmark/Tour50">Results</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour51">Characterization</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour52">Two-Hybrid System</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour53">Submitted Parts</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour54">Interlab Study</A></LI></UL><UL><LI class="header"><A href="https://2015.igem.org/Team:SDU-Denmark/Tour60">Practices</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour61">Survey</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour62">Education</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour63">Ethics</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour64">A Children's Book</A></LI></UL><UL><LI class="header"><A href="https://2015.igem.org/Team:SDU-Denmark/Tour70">
What is Next?</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour71">Challenges and Limitations</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour72">Medical Aspects</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour72">Lab Work</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour73">The End</A></LI></UL></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV><DIV class="tourBoundingBox"><DIV class="tourBoundingBoxInner bannerShadow"><DIV class="parentTourItem "><A class="tourItemLabel" title="Get a brief overview of the project.">
                Introduction
            </A></DIV><DIV class="expandedTour" style="display:none"><DIV class="expandedTourInner"><DIV class="parentTourItem"><A class="tourItemLabel" title="Would you like to meet our team?">
                       The Team
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="To express our thankfulness.">
                        Attributions
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Gallery
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Medal Requirements
                    </A></DIV></DIV></DIV><DIV class="parentTourItem "><A class="tourItemLabel" title="">
               Antibody issue
            </A></DIV><DIV class="expandedTour" style="display:none"><DIV class="expandedTourInner"><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                       Antibody production
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Animal Ethics
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        The Alternative
                    </A></DIV></DIV></DIV><DIV class="parentTourItem "><A class="tourItemLabel" title="">
                PAST            </A></DIV><DIV class="expandedTour" style="display:none"><DIV class="expandedTourInner"><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Two-Hybrid Screening
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        System Design
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Business
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                       Entrepreneurship
                    </A></DIV></DIV></DIV><DIV class="parentTourItem "><A class="tourItemLabel" title="">
                Process
            </A></DIV><DIV class="expandedTour" style="display:none"><DIV class="expandedTourInner"><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Complete Journal
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Collaborations
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                       SOPs
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Safety
                    </A></DIV></DIV></DIV><DIV class="parentTourItem "><A class="tourItemLabel" title="">       Results
            </A></DIV><DIV class="expandedTour" style="display:none"><DIV class="expandedTourInner"><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Characterization
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                      Two-Hybrid System
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                       Submitted Parts
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Interlab Study
                    </A></DIV></DIV></DIV><DIV class="parentTourItem "><A class="tourItemLabel" title="">
Practices
            </A></DIV><DIV class="expandedTour" style="display:none"><DIV class="expandedTourInner"><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Survey
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Education
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Ethics
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title=""> A Children’s Book
                    </A></DIV></DIV></DIV><DIV class="parentTourItem "><A class="tourItemLabel" title="">
               What is Next
            </A></DIV><DIV class="expandedTour" style="display:none"><DIV class="expandedTourInner"><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Challenges and Limitations
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Medical Aspects
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Lab Work
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                      The End
                    </A></DIV></DIV></DIV></DIV></DIV><DIV class="MainLayout"><DIV class="content"><P><I> &quot;Alberto is an expert in the disposal business.&quot; - <B>Alejandro Sosa: Scarface</B></I></P><H1 align="center"> Business </H1><DIV class="thumb tright"><DIV class="thumbinner" style="width:185px; height:200px;"><DIV class="thumbcaption">Figure 1: Business model canvas for PAST. </DIV></DIV></DIV><P><SPAN class="intro">We in PAST</SPAN> believe that our product is a valuable addition to the toolbox of researchers and educators. But believing is not knowing, and therefore an investigation was conducted to conclude whether this presumption is wrong. This evaluation consists of a business canvas, a market analysis based on iGEM teams from 2014 and a cost analysis, allowing us to assess if profit margins are large enough to verify our assumption.
</P><P><SPAN class="intro">A market analysis</SPAN> was conducted to determine how many batches PAST should be able to produce per year. The analysis is based on the competitors of iGEM 2014. These teams are at the forefront of synthetic biology and therefore it is assumed, that they represent the future of the field. Every team who has succeeded in making their wiki has been considered. The results can be viewed in the following pdf (<A target="_blank" href="https://static.igem.org/mediawiki/2015/8/81/SDU2015_Market_analysis_the_iGEM_2014.pdf">Market analysis iGEM 2014</A>). 

</P><DIV class="accordion" style="width:100%;"><DIV class="accordionTitel"> Team distribution  </DIV><DIV class="pane" style="height:auto;"><DIV class="thumb tright"><DIV class="thumbinner" style="width:205px; height:230px;"><DIV class="thumbcaption">Figure 2: Chart of the global distribution of teams</DIV></DIV></DIV><P><SPAN class="intro">The market is presumed</SPAN> to be worldwide. The distribution of teams, which can be viewed in  figure 2, shows an even distribution in all but one region. This underrepresentation by Latin America can be caused by several factors, but for now it is considered a future market, and no correlations will be made.

</P></DIV><DIV class="accordionTitel"> Teams using antibodies  </DIV><DIV class="pane" style="height:auto;"><DIV class="thumb tright"><DIV class="thumbinner" style="width:205px; height:230px;"><DIV class="thumbcaption">Figure 3: Chart of teams using antibodies distributed in regions</DIV></DIV></DIV><P><SPAN class="intro">We have investigated</SPAN> how many teams according to regions that have used antibodies in their project. The results are depicted in  figure 3. Though Europe only represents 28 % of the total teams, these teams use 55% of the totale usage of antibodies, whereas North American teams used antibodies half as much as they are represented.
Several reasons can be responsible for this under- and overrepresentation. If it is assumed, that all teams producing proteins could potentially use antibodies, it is a possibility that projects on this subject is more common in Europe than in North America. This will be investigated next.


</P></DIV><DIV class="accordionTitel"> Teams producing proteins  </DIV><DIV class="pane" style="height:auto;"><DIV class="thumb tright"><DIV class="thumbinner" style="width:205px; height:230px;"><DIV class="thumbcaption">Figure 4: Chart of teams producing protein in regards to regions</DIV></DIV></DIV><P><SPAN class="intro">Figure 4 shows</SPAN> that the teams producing proteins follow the general distribution globally, therefore there is no correlation between protein production and the uneven distribution of antibody usage. It has not been possible to determine if resources is the cause of the bias, but this does not seem unreasonable. If that is the case, teams will benefit from PAST’s product globally.

</P><P><SPAN class="intro">Teams producing proteins</SPAN>  and teams using antibodies has been compared in figure 4. This shows that only a few actually use antibodies. This could be due to teams not reaching a point, where assays using antibodies are necessary, rather than a lack of resources. However, it has been decided to ignore this as a reason, since it must be assumed, that research projects generally have more time to evolve. Therefore it has been decided to base the estimate of production size on the protein production rather than antibody usage.
</P><DIV class="thumb tright"><DIV class="thumbinner" style="width:205px; height:260px;"><DIV class="thumbcaption">Figure 5:comparison of protein production and antibody usage</DIV></DIV></DIV><P><SPAN class="intro">Using the assumption</SPAN> an estimate can be made. A total of 123 teams where involved in projects producing proteins, and on average the teams used two types of antibodies per project. Therefore a production of approximately 250 varieties of peptide aptamers is presumed appropriate. Though this estimates the number of batches per year, each project will only buy a small amount of the production. Therefore it should be evaluated if, it is reasonable to assume that the rest of the production can be sold as well. To reach a conservative estimate the European market has been evaluated, as this is the region where most antibodies where used. 63 universities were represented at iGEM 2014 out of approximately 4000 academic institutions in Eur<SPAN class="sourceReference">ope</SPAN>. 
<SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
European Union. The role of universities in the Europe of knowledge. <A target="_blank" href="http://eur-lex.europa.eu/legal-

content/EN/TXT/?uri=URISERV:c11067">(Link)</A> (Accessed August 21<SUP>st</SUP> 2015).
</SPAN>  

Taking these numbers into consideration, iGEM 2014 represents 1.6 % of the market. Assuming only one research project per university is using antibodies, which is unlikely, this evaluation reinforces the assumption, that the remaining product can be sold. In some instances this will not be the case, due to the specialized nature of production or property rights. Therefore it is estimated that 30 % of the production will be lost.

</P></DIV></DIV><P><SPAN class="intro">A cost analysis</SPAN> is key in estimating profitability, and determining if this project should be carried on after iGEM. These estimates shows if our presumption of the competitiveness are wrong rather than right. The analysis is used to approximate the pricing of the product, since it does not exist on the market as of yet. The aim is to reduce prices by half in comparison to the price of mAbs, which leaves an acceptable margin between reality and estimates.
</P><DIV class="accordion" style="width:100%;"><DIV class="accordionTitel"> Capital Investment  </DIV><DIV class="pane" style="height:auto;"><P>
To estimate how much capital is needed to build the plant, the Busche model (1995) with modifications has 

been us<SPAN class="sourceReference">ed</SPAN>. 
<SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and
Evaluation; Third Edition - International Student Version; John Wiley &amp; Sons, Inc.; 2010
</SPAN> 

The size of the factory has to be estimated before costs can be calculated, and therefore it is necessary to 

evaluate the number of units needed. As established under <A target="_blank" href="https://2015.igem.org/Team:SDU-Denmark/Tour34">entrepreneurship</A> it has been decided to 

produce several small batches, and the market analysis estimated the amount of batches to be 250 per year. According to the timeline a batch cycle is 63.5 [h], and the next batch can begin after a flash 

sterilization of the fermenter, 42.5 [h] from the start of the batch. This implies, that the cycle time of 

two batches is 106 [h]. It is assumed that the plant is closed for 4 [weeks/yr] and a work week consists of 5 

days (120 [h]). Which means that 3 set-ups are needed. This assumption leaves a time buffer in case of 

unforeseen maintenance or orders.
</P><P><TABLE class="wikitable"><CAPTION><B> Table 1: Estimate of the total capital investment</B></CAPTION><TBODY><TR><TD>Result [million USD]	</TD><TD>Source:</TD></TR><TR><TD><B>Total bare-module investment	</B></TD><TD>7.6	</TD><TD><SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and
Evaluation; Third Edition - International Student Version; John Wiley &amp; Sons, Inc.; 2010
</SPAN>  chapter 22.3

Simulation Aspen Plus, method BK10
<SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
E-mail from GE lifescienses
</SPAN>  linear extrapolation of price development
</TD></TR><TR><TD>Cost of site preparation	</TD><TD>1.1	</TD><TD><SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and
Evaluation; Third Edition - International Student Version; John Wiley &amp; Sons, Inc.; 2010
</SPAN>  chapter 22.3</TD></TR><TR><TD>Cost of service facilities	</TD><TD>0.6	</TD><TD><SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and
Evaluation; Third Edition - International Student Version; John Wiley &amp; Sons, Inc.; 2010
</SPAN>  chapter 22.3</TD></TR><TR><TD>Allocated costs for utility plants and related facilities	</TD><TD>2.9	</TD><TD><SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and
Evaluation; Third Edition - International Student Version; John Wiley &amp; Sons, Inc.; 2010
</SPAN>  chapter 22.3; table 22.12  Simulation Aspen Plus, method BK10</TD></TR><TR><TD><B>Total direct permanent investment	</B></TD><TD><B>12.2	</B></TD><TD><SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and
Evaluation; Third Edition - International Student Version; John Wiley &amp; Sons, Inc.; 2010
</SPAN>  chapter 22.3</TD></TR><TR><TD>Cost of contingencies and contractor’s fee	</TD><TD>2.2	</TD><TD><SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and
Evaluation; Third Edition - International Student Version; John Wiley &amp; Sons, Inc.; 2010
</SPAN>  chapter 22.3</TD></TR><TR><TD><B>Total depreciable capital	</B></TD><TD><B>14.4	</B></TD><TD><SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and
Evaluation; Third Edition - International Student Version; John Wiley &amp; Sons, Inc.; 2010
</SPAN>  chapter 22.3</TD></TR><TR><TD>Cost of land	</TD><TD>0.3	</TD><TD><SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and
Evaluation; Third Edition - International Student Version; John Wiley &amp; Sons, Inc.; 2010
</SPAN>  chapter 22.3</TD></TR><TR><TD>Cost of plant startup	</TD><TD>3.6	</TD><TD><SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and
Evaluation; Third Edition - International Student Version; John Wiley &amp; Sons, Inc.; 2010
</SPAN>  chapter 22.3</TD></TR><TR><TD><B>Total permanent investment	</B></TD><TD><B>21.6	</B></TD><TD><SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and
Evaluation; Third Edition - International Student Version; John Wiley &amp; Sons, Inc.; 2010
</SPAN> chapter 22.3</TD></TR><TR><TD>Working capital	</TD><TD>3.2	</TD><TD><SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and
Evaluation; Third Edition - International Student Version; John Wiley &amp; Sons, Inc.; 2010
</SPAN>  chapter 22.3</TD></TR><TR><TD><B>Total captital investment	</B></TD><TD><B>24.9	</B></TD><TD><SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and
Evaluation; Third Edition - International Student Version; John Wiley &amp; Sons, Inc.; 2010
</SPAN>  chapter 22.3</TD></TR></TBODY></TABLE></P><P>
Note: several minor cost calculations such as that of pumps has been ignored.
</P><P>
This calculation shows that an investment of 24.9 [million USD] is needed to get the plant up and running. 
</P></DIV><DIV class="accordionTitel"> Cost of Production </DIV><DIV class="pane" style="height:auto;"><P>
An approximation on the annual production cost needs to be estimated, this is achieved by

usage of the Busche model (1995) with modificatio<SPAN class="sourceReference">ns</SPAN>. 
<SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and
Evaluation; Third Edition - International Student Version; John Wiley &amp; Sons, Inc.; 2010
</SPAN><TABLE class="wikitable"><CAPTION><B>Table 3: </B></CAPTION><THEAD><TR><TD>Result [million USD/yr]</TD><TD>Source:</TD></TR></THEAD><TBODY><TR><TD><B>Total Feedstock	</B></TD><TD><B>3.5</B></TD><TD>Entrepreneurship
<SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Available from:
<A target="_blank" href="https://www.sigmaaldrich.com/denmark.html">[Sigma-Aldrich] (accessed: 10.09.2015)
</A></SPAN>  Sigma-Aldrich 
<SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Available at:
<A target="_blank" href="https://www.neb.com/products/e8036-chitin-magnetic-beads">[NEB] (accessed: 13.09.2015)
</A></SPAN>   NEB </TD></TR><TR><TD>Electricity	</TD><TD>0.3	</TD><TD>Simulation Aspen Plus, methods BK10 and Water</TD></TR><TR><TD>Cooling water	</TD><TD>0.00004</TD><TD>	Simulation Aspen Plus, methods BK10 and Water</TD></TR><TR><TD>Process water	</TD><TD>0.003	</TD><TD>Entrepreneurship </TD></TR><TR><TD><B>Total utilities	</B></TD><TD><B>0.32	</B></TD><TD><SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and
Evaluation; Third Edition - International Student Version; John Wiley &amp; Sons, Inc.; 2010
</SPAN>  Chapter 23.2</TD></TR><TR><TD>Direct wages and benefits</TD><TD>	1.09	</TD><TD><SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and
Evaluation; Third Edition - International Student Version; John Wiley &amp; Sons, Inc.; 2010
</SPAN>  Equation 23.2 and table 23.3</TD></TR><TR><TD>Direct salaries and benefits</TD><TD>	0.16	</TD><TD><SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and
Evaluation; Third Edition - International Student Version; John Wiley &amp; Sons, Inc.; 2010
</SPAN>  Chapter 23.2</TD></TR><TR><TD>Operating supplies and services	</TD><TD>0.07	</TD><TD><SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and
Evaluation; Third Edition - International Student Version; John Wiley &amp; Sons, Inc.; 2010
</SPAN>  Chapter 23.2</TD></TR><TR><TD>Technical assistance to manufacturing	</TD><TD>0.02	</TD><TD><SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and
Evaluation; Third Edition - International Student Version; John Wiley &amp; Sons, Inc.; 2010
</SPAN>  Chapter 23.2</TD></TR><TR><TD>Control laboratory	</TD><TD>0.02	</TD><TD><SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and
Evaluation; Third Edition - International Student Version; John Wiley &amp; Sons, Inc.; 2010
</SPAN>  Chapter 23.2</TD></TR><TR><TD><B>Total labor-related Operations</B></TD><TD><B>1.4	</B></TD><TD><SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and
Evaluation; Third Edition - International Student Version; John Wiley &amp; Sons, Inc.; 2010
</SPAN>  Chapter 23.2</TD></TR><TR><TD>Wages and benefits	</TD><TD>0.6	</TD><TD><SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and
Evaluation; Third Edition - International Student Version; John Wiley &amp; Sons, Inc.; 2010
</SPAN>  Chapter 23.2</TD></TR><TR><TD>Salaries and benefits	</TD><TD>0.2	</TD><TD><SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and
Evaluation; Third Edition - International Student Version; John Wiley &amp; Sons, Inc.; 2010
</SPAN>  Chapter 23.2</TD></TR><TR><TD>Materials and services	</TD><TD>0.6	</TD><TD><SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and
Evaluation; Third Edition - International Student Version; John Wiley &amp; Sons, Inc.; 2010
</SPAN>  Chapter 23.2</TD></TR><TR><TD>Maintenance overhead	</TD><TD>0.03	</TD><TD><SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and
Evaluation; Third Edition - International Student Version; John Wiley &amp; Sons, Inc.; 2010
</SPAN>  Chapter 23.2</TD></TR><TR><TD><B>Total Maintenance</B></TD><TD><B>1.5</B></TD><TD><SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and
Evaluation; Third Edition - International Student Version; John Wiley &amp; Sons, Inc.; 2010
</SPAN>  Chapter 23.2</TD></TR><TR><TD>General plant overhead	</TD><TD>0.1	</TD><TD><SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and
Evaluation; Third Edition - International Student Version; John Wiley &amp; Sons, Inc.; 2010
</SPAN>  Chapter 23.2</TD></TR><TR><TD>Mechanical department services	</TD><TD>0.05	</TD><TD><SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and
Evaluation; Third Edition - International Student Version; John Wiley &amp; Sons, Inc.; 2010
</SPAN>   Chapter 23.2</TD></TR><TR><TD>Employee relations department	</TD><TD>0.1	</TD><TD><SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and
Evaluation; Third Edition - International Student Version; John Wiley &amp; Sons, Inc.; 2010
</SPAN>  Chapter 23.2</TD></TR><TR><TD>Business services	</TD><TD>0.2	</TD><TD><SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and
Evaluation; Third Edition - International Student Version; John Wiley &amp; Sons, Inc.; 2010
</SPAN>  Chapter 23.2</TD></TR><TR><TD><B>Total operation overhead </B></TD><TD><B>0.47</B></TD><TD><SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and
Evaluation; Third Edition - International Student Version; John Wiley &amp; Sons, Inc.; 2010
</SPAN>  Chapter 23.2</TD></TR><TR><TD><B>Property taxes and insurance	</B></TD><TD><B>0.3	</B></TD><TD><SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and
Evaluation; Third Edition - International Student Version; John Wiley &amp; Sons, Inc.; 2010
</SPAN>  Chapter 23.2</TD></TR><TR><TD>Direct plant	</TD><TD>0.88	</TD><TD><SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and
Evaluation; Third Edition - International Student Version; John Wiley &amp; Sons, Inc.; 2010
</SPAN>  Chapter 23.2</TD></TR><TR><TD>Allocated plant	</TD><TD>0.21	</TD><TD><SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and
Evaluation; Third Edition - International Student Version; John Wiley &amp; Sons, Inc.; 2010
</SPAN>  Chapter 23.2</TD></TR><TR><TD><B>Total depreciation	</B></TD><TD><B>1.08	</B></TD><TD><SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and
Evaluation; Third Edition - International Student Version; John Wiley &amp; Sons, Inc.; 2010
</SPAN>  Chapter 23.2</TD></TR><TR><TD><B>Total cost of manufacturing</B></TD><TD><B>8.6	</B></TD><TD><SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and
Evaluation; Third Edition - International Student Version; John Wiley &amp; Sons, Inc.; 2010
</SPAN> Chapter 23.2</TD></TR><TR><TD><B>Total general expenses	</B></TD><TD><B>0.2	</B></TD><TD><SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Available at:
<A target="_blank" href="http://www.rand.org/content/dam/rand/pubs/monograph_reports/MR1325/MR1325.ch9.pdf "> (accessed: 15.09.2015)
</A></SPAN>   Rand Corporation</TD></TR><TR><TD><B>Total cost of production	</B></TD><TD><B>8.8	</B></TD><TD><SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and
Evaluation; Third Edition - International Student Version; John Wiley &amp; Sons, Inc.; 2010
</SPAN>  Chapter 23.2</TD></TR></TBODY></TABLE></P><P>
This concludes that according to the model, it will cost 8.8 [million USD/yr] for PAST to produce 250 

batches.
</P></DIV><DIV class="accordionTitel"> Pricing and Profitability </DIV><DIV class="pane" style="height:auto;"><P>
The challenge of biotech companies is to price a product that is of yet not on the market. This has to be an 

evaluation of the costs estimated above and the investments needed for maturing the concept on one 

hand, and how much customers are willing to pay on the other. PAST aims to replace mAbs, and it must be 

assumed that though there are concerns of animal welfare, the customers will be inclined to keep using 

mAbs, if the price of the peptide aptamers are not considerably lower. Therefore an average of the price of

mAbs has been estimated by 50 products from Sigma-Aldrich, details can be viewed in the following pdf (<A target="_blank" href="https://static.igem.org/mediawiki/2015/0/01/SDU2015_sigma-aldrich_antibodies.pdf">Sigma-Aldrich antibodies</A>). Assessment of the pricing shows an average price of 1.7 [million USD/g]. This method of pricing presupposed that the peptide aptamers have 

the same affinity and specificity as mAbs. The definition of sales can be viewed in equation 1, and it should be 

noted that it is assumed that 30 % of production is lo<SPAN class="sourceReference">st</SPAN>. 
<SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and
Evaluation; Third Edition - International Student Version; John Wiley &amp; Sons, Inc.; 2010
</SPAN></P><P style="margin-left:320px;">	S=Price x 0.70Production	(1)</P><P>
In figure 5 net earnings can be viewed. Net earnings has been calculated from equation <SPAN class="sourceReference">2</SPAN>. 
<SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and
Evaluation; Third Edition - International Student Version; John Wiley &amp; Sons, Inc.; 2010
</SPAN></P><P style="margin-left:310px;">	Net earnings = (1 - t)(S - C) (2)</P><P style="margin-left:310px;">where C=Cost of production</P><P style="margin-left:310px;">and t=Property taxes and insurance</P><P>
The goal of PAST is to sell the product at least 50% cheaper than of mAbs. Figure 5 shows that PAST will render positive net earnings and achieve this goal at prices in the range of 1.5-50% of mAbs.These calculations does not take into account the investments in the plant. Therefore three different methods were used for estimating the profitability, see table 3. They cannot be compared directly, but if all shows profitability, it must be assumed, that grounds to work further with the idea is establish<SPAN class="sourceReference">ed</SPAN>. 
<SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and
Evaluation; Third Edition - International Student Version; John Wiley &amp; Sons, Inc.; 2010
</SPAN></P><DIV class="thumb tright"><DIV class="thumbinner" style="width:255px; height:230px;"><DIV class="thumbcaption">Figure 6: Net earnings compared to the price of mAbs, it is noted that within the range of 1.5-50% of the price of mAbs, the net earnings are positive. </DIV></DIV></DIV><P><TABLE class="wikitable" style="width:62%;"><CAPTION><B>Table 3:</B> methods of evaluating profitability</CAPTION><THEAD><TR><TD>Method</TD><TD> Equation 	   </TD><TD> Source </TD></TR></THEAD><TBODY><TR><TD>Return of investment	</TD><TD> ROI=(1-t)(S-C)/C<SUB>TCI</SUB></TD><TD><SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and
Evaluation; Third Edition - International Student Version; John Wiley &amp; Sons, Inc.; 2010
</SPAN> table 22.5 </TD></TR><TR><TD> C<SUB>TCI=Total capital investment 	 </SUB></TD></TR><TR><TD>Payback period	  </TD><TD>PBP=C<SUB>TDC</SUB>/((1-t)(S-C)+D)	            </TD><TD><SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and
Evaluation; Third Edition - International Student Version; John Wiley &amp; Sons, Inc.; 2010
</SPAN> table 22.5</TD></TR><TR><TD> C<SUB>TDC=Total depriciable cost 	 </SUB></TD></TR><TR><TD> D=Depriciation	 </TD></TR><TR><TD>Venture profit	        </TD><TD>VP=(1-t)(S-C)-i<SUB>min</SUB> C<SUB>TCI</SUB></TD><TD><SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and
Evaluation; Third Edition - International Student Version; John Wiley &amp; Sons, Inc.; 2010
</SPAN> table 22.5</TD></TR></TBODY></TABLE></P><DIV class="thumb tright"><DIV class="thumbinner" style="width:255px; height:220px;"><DIV class="thumbcaption">Figure 7: Evaluation of profitability  </DIV></DIV></DIV><P>
The goal is to sell the peptide aptamers at least at 50 % of the price of mAbs, therefore the methods are used for a price range between 1-50 %. Parameters for profitability of the three methods are: ROI&gt;0 %, PBP&lt;2 [yr]  and VP&gt;0 [million/yr]. Results can viewed in figu<SPAN class="sourceReference">re</SPAN>. 
<SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and
Evaluation; Third Edition - International Student Version; John Wiley &amp; Sons, Inc.; 2010
</SPAN></P><P>
The evaluation shows, that PAST will be profitable at a price above 4 % that of mAbs, which corresponds to a price of 0.07 [million USD/g]. It is most unlikely that investors can be paid back at this price, and should be taken as an indication of the margin in pricing. In this estimate it will be possible to raise prices by 44 % before exceeding the goal. Another uncertainty is the validity of the estimate, since this is only an approximation of reality. Therefore the same calculations were done, if the cost turns out to be double. This showed profitability at a price set at 8 % that of mAbs, which corresponds to a price of 0.13 [million USD/g]. 
This leads to the conclusion, that there is a good possibility of making a profitable enterprise, and it should be encourage to keep working towards more accurate estimates and finally the realization of PAST. 
</P></DIV></DIV></DIV><DIV class="footer "><DIV class="footerContainer"><A class="footerBtn footerShadow" id="btnFastForward"><P class="footerBtnPre">Next chapter
</P></A><A class="footerBtn footerShadow" id="btnNextChapter"><P class="footerBtnPre">Next chapter
</P></A><A class="footerBtn footerShadow" id="btnDigDeeper"><P class="footerBtnPre">Dig deeper
</P></A><A class="footerBtn footerShadow" id="btnTheEnd" href="http://www.igem.org" target="_blank"><P class="footerBtnPre">End of tour
</P><P class="footerBtnHeader" style="text-transform: none !important;">Want more? Go to iGEM.org!</P><P class="footerBtnText">
If you want to learn more about Synthetic Biology you should visit iGEM's homepage, which contains loads on the subject. You can even visit other teams' wikis and take a look at what they accomplished. Or maybe join a team yourself?</P></A></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>